(Q44991866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Ahwon Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Byung Joo Chae

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Ja-Seong Bae

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Byung Joo Song

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Sang Seol Jung

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

11 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

Journal of Surgical Oncology

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

807-812

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

12 March 2020

cites work

1 reference

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

Understanding and targeting osteoclastic activity in prostate cancer bone metastases

21 January 2018

1 reference

The RANK/RANKL/OPG triad in cancer-induced bone diseases

21 January 2018

1 reference

Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss

21 January 2018

1 reference

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.

21 January 2018

1 reference

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

21 January 2018

1 reference

Progesterone induces adult mammary stem cell expansion

21 January 2018

1 reference

Targeting RANKL in breast cancer: bone metastasis and beyond

21 January 2018

1 reference

Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma

21 January 2018

1 reference

Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours

21 January 2018

1 reference

Expression of nuclear receptor DAX-1 and androgen receptor in human breast cancer

21 January 2018

1 reference

p53 as a specific prognostic factor in triple-negative breast cancer

21 January 2018

1 reference

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

Effects of bone-targeted agents on cancer progression and mortality.

21 January 2018

1 reference

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

21 January 2018

1 reference

Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients

21 January 2018

1 reference

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.23737

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25111682%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference